Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Isis Stories

2013-10-08 04:20:34

LONDON, Oct. 8, 2013 /PRNewswire/ -- The GSMA today announced details of the NFC Experience at the NFC & Mobile Money Summit 2013, which will be delivered in conjunction with Isis, the NFC Experience Official Sponsor. All show attendees with NFC-enabled smartphones will be able to participate in the NFC Experience at this year's NFC & Mobile Money Summit, which will take place at the Metropolitan Pavilion in New York on 14-17 October. Services showcased in the NFC Experience...

2013-10-07 08:24:46

CARLSBAD, Calif., Oct. 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that GlaxoSmithKline (GSK) has added a development candidate ISIS-GSK3(Rx), to its collaboration with Isis. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3(Rx) is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3(Rx) to Phase 2...

2013-10-03 16:23:10

--Isis earns $2 million milestone payment-- CARLSBAD, Calif., Oct. 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it dosed the first infant in the 12 mg dose group in the Phase 2 study evaluating ISIS-SMN(Rx) in infants with Type I spinal muscular atrophy (SMA). The Phase 2 study is designed to allow Isis to define the optimal dose for the larger Phase 2/3 study in infants and to provide safety and tolerability data. Isis plans to complete...

2013-09-26 16:29:33

Kicking off MobileCON(TM) 2013, Dan Mead (Verizon Wireless) joins industry leaders from American Express, Isis and Jamba Juice; AirWatch, CA Technologies, Good Technology, Juniper Networks and TechRepublic on the MobileCON keynote stage. WASHINGTON, Sept. 26, 2013 /PRNewswire-USNewswire/ -- CTIA-The Wireless Association® today announced the experts and thought leaders who will appear as keynote presenters and panelists at MobileCON(TM) 2013. Attendees will first hear from Dan Mead,...

2013-09-25 08:29:05

CARLSBAD, Calif., Sept. 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Leerink Swann Rare Disease Roundtable on Wednesday, October 2, 2013 at 2:20 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's...

2013-09-22 08:20:22

CARLSBAD, Calif., Sept. 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that Isis will conduct a live webcast and slide presentation conference call at 11:30 a.m. Eastern Time on Monday, September 23 to discuss ISIS-APOCIII(Rx) Phase 2 data in patients with familial chylomicronemia syndrome. These data were presented on Saturday, September 21, 2013 at the National Lipid Association clinical lipid update...

2013-09-21 12:22:07

Reductions of more than 1,500 mg/dL in triglycerides observed CARLSBAD, Calif., Sept. 21, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced data from a Phase 2 study of ISIS-APOCIII(Rx) as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. FCS is a rare orphan disease characterized by severely high triglyceride levels that affects an estimated 3,000 to 5,000 patients worldwide. These data were presented today by Dr. Daniel Gaudet at...

2013-09-19 08:28:04

Improvements in muscle function continue to be observed up to fourteen months after a single dose CARLSBAD, Calif., Sept. 19, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA), show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function...

2013-09-18 16:26:18

CARLSBAD, Calif., Sept. 18, 2013 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2013 Director of the Year Award for Companies in Transition. Each year the Corporate Directors Forum, a non-profit organization that promotes high standards of professionalism in corporate governance, recognizes directors for their high standards in corporate governance. Dr. Crooke is...

2013-09-09 08:26:40

--Biogen Idec and Isis to leverage antisense technology to accelerate discovery and development of novel therapies-- WESTON, Mass. and CARLSBAD, Calif., Sept. 9, 2013 /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the companies have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's expertise in neurology with Isis'...